Public health researchers need to understand why people diagnosed with hepatitis C do not begin or complete treatment, but the answer often sits across program data, interview transcripts, language differences, and healthcare experiences. AI qualitative analysis of hepatitis C treatment access can help research teams organize these materials into defensible themes without reducing patient stories to percentages. Evidano is an AI-powered qualitative data analysis platform that helps researchers analyze interviews, open-ended surveys, and public health documents. The November 20, 2026 PLoS One study from Los Angeles County provides a useful example: quantitative data showed how frequently barriers occurred, while interviews explained why cost, language, transportation, provider delays, and limited treatment knowledge affected care. This article summarizes the study and translates its mixed-methods design into a practical workflow for public health, healthcare, and qualitative research teams.
Run this analysis on your own data
Start freeTopics
- AI qualitative analysis of hepatitis C treatment access
- qualitative analysis of hepatitis C barriers
- AI thematic analysis public health research
- hepatitis C patient interviews
Run this analysis on your own data
Evidano codes documents, interviews, survey responses and spreadsheets with AI, with your judgment in control at every step.
Keep reading
- Commentary on NewsAI Qualitative Analysis of Hepatitis C BarriersLearn how AI qualitative analysis of hepatitis C barriers turns interviews and program data into actionable insights for public health and care teams.
- Commentary on NewsQualitative Analysis of Perioperative HypothermiaLearn how qualitative analysis of perioperative hypothermia reveals clinical barriers, and see how AI helps healthcare teams synthesize interviews faster.
- Commentary on NewsAI Qualitative Analysis: HCV Access LessonsLearn how AI qualitative analysis helps healthcare teams interpret HCV access research, compare patient segments, and turn interviews into equitable action with Evidano.
